Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
S-8

Securities offered to employees pursuant to employee benefit plans

 View HTML
0001558370-20-005420.pdf
0001558370-20-005420.rtf
0001558370-20-005420.xls
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

 View HTML
0001558370-20-004625.pdf
0001558370-20-004625.rtf
0001558370-20-004625.xls
DEFA14A

Additional proxy soliciting materials - definitive

 View HTML
0001558370-20-004641.pdf
0001558370-20-004641.rtf
0001558370-20-004641.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-20-004422.pdf
0001558370-20-004422.rtf
0001558370-20-004422.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-20-004434.pdf
0001558370-20-004434.rtf
0001558370-20-004434.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000315066-20-001428.pdf
0000315066-20-001428.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-004742.pdf
0001179110-20-004742.rtf
0001179110-20-004742.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-20-003494.pdf
0001558370-20-003494.rtf
0001558370-20-003494.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-004115.pdf
0001179110-20-004115.rtf
0001179110-20-004115.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-20-004114.pdf
0001179110-20-004114.rtf
0001179110-20-004114.xls